Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Next, we investigated the effects of lncRNA FAF on angiotensinogen II (Ang II)-induced cardiac fibrosis in neonatal rat CFs and explored the mechanism underlying these effects.
|
31708099 |
2020 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Steroidogenic acute regulatory protein/aldosterone synthase mediates angiotensin II-induced cardiac fibrosis and hypertrophy.
|
31820314 |
2020 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Opposite Effects of Moderate and Extreme Cx43 Deficiency in Conditional Cx43-Deficient Mice on Angiotensin II-Induced Cardiac Fibrosis.
|
31652649 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endothelial-specific deletion of Ets-1 attenuates Angiotensin II-induced cardiac fibrosis via suppression of endothelial-to-mesenchymal transition.
|
30670148 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Echocardiographic analysis, Sirius Red staining and immunofluorescence staining were performed to investigate the function of circHIPK3 in angiotensin II (Ang II) induced cardiac fibrosis in vivo.
|
30967276 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Protocatechuic acid attenuates angiotensin II-induced cardiac fibrosis in cardiac fibroblasts through inhibiting the NOX4/ROS/p38 signaling pathway.
|
31318113 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD44 Deficiency in Mice Protects the Heart Against Angiotensin Ii-Induced Cardiac Fibrosis.
|
29470359 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (AngII) has been implicated in the development of cardiac fibrosis.
|
31640463 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results together reveal that IMM-H007 improves heart function, and alleviates AngII-induced cardiac fibrosis by regulating AMPK-TGF-β1 signaling.
|
31181209 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, the potential role of AHR signaling in the development of left ventricular hypertrophy and cardiac fibrosis by angiotensin II (Ang II) infusion was investigated in mice lacking the AHR gene (Ahr<sup>-/-</sup>).
|
31016362 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, we here identified irisin as a promising anti-fibrotic therapeutic for angiotensin II-related cardiac fibrosis.
|
30703374 |
2019 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (Ang II), an effective component of renin-angiotensin system, plays a pivotal role in cardiac fibrosis, which may further contribute to heart failure.
|
30369577 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endogenous Insl6 protein inhibits cardiac systolic dysfunction and cardiac fibrosis in angiotensin II- and isoproterenol-induced cardiac stress models.
|
29887522 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that macrophages when recruited into the heart and aorta from the spleen potentially contribute to angiotensin II-induced cardiac fibrosis and hypertension.
|
28490219 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results of histopathological analysis, as well as measurements of collagen expression and cardiac fibroblast proliferation indicated that puerarin administration significantly inhibited cardiac fibrosis induced by AB and AngII.
|
29928229 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we found that A77 1726 treatment attenuated pressure overload or angiotensin II (Ang II)-induced cardiac hypertrophy <i>in vivo</i>, as well as agonist-induced hypertrophic response of cardiomyocytes <i>in vitro</i> In addition, we showed that A77 1726 administration prevented induction of cardiac fibrosis by inhibiting cardiac fibroblast (CF) transformation into myofibroblast.
|
29540538 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here we describe the use a highly selective TG2 small-molecule inhibitor to test the efficacy of TG2 inhibition as an anti-fibrotic therapy for heart failure employing two different in vivo models of cardiac fibrosis: Progressively induced interstitial cardiac fibrosis by pressure overload using angiotensin II infusion: Acutely induced focal cardiac fibrosis through myocardial infarction by ligation of the left anterior descending coronary artery (AMI model).
|
29795262 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the potential anti-myocardial fibrosis effect and mechanism of SalB on Angiotensin II (Ang II)-induced cardiac fibrosis in vitro.
|
30365482 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glaucocalyxin A attenuates angiotensin II-induced cardiac fibrosis in cardiac fibroblasts.
|
30072098 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Angiotensin II (Ang II) plays an important role on the pathogenesis of cardiac fibrosis.
|
29322373 |
2018 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice.
|
28474247 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mice in which αv integrin is depleted in PDGFRβ<sup>+</sup> cells are protected from cardiotoxin and laceration-induced skeletal muscle fibrosis and angiotensin II-induced cardiac fibrosis.
|
29061963 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of microRNA‑155 ameliorates cardiac fibrosis in the process of angiotensin II‑induced cardiac remodeling.
|
28944921 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Erratum to: Inhibition of Angiotensin II-Induced Cardiac Fibrosis by Atorvastatin in Adiponectin Knockout Mice.
|
29030734 |
2017 |
Cardiac fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endothelial-to-mesenchymal transition (EndMT) is a mechanism that promotes cardiac fibrosis induced by Angiotensin II (AngII).
|
29073623 |
2017 |